Dị ka ọgwụ mgbochi ọnụ ọhụrụ, a na-eji rivaroxaban eme ihe n'ọtụtụ ebe na mgbochi na ọgwụgwọ ọrịa thromboembolic venous na mgbochi ọrịa strok na-abụghị valvular atrial fibrillation.Iji jiri rivaroxaban mee ihe n'ụzọ ziri ezi, ị kwesịrị ịma ma ọ dịkarịa ala isi ihe atọ ndị a.
I. Ọdịiche dị n'etiti rivaroxaban na ọgwụ mgbochi ọnụ ndị ọzọ Ugbu a, ọgwụ mgbochi ọnụ nke a na-ejikarị gụnyere warfarin, dabigatran, rivaroxaban na ndị ọzọ.N'ime ha, a na-akpọ dabigatran na rivaroxaban ọhụrụ anticoagulants (NOAC).Warfarin, na-eme ka mmetụta ya na-eme ka ọ ghara ịmịnye ọbara site na igbochi njikọ nke coagulation factor II (prothrombin), VII, IX na X. Warfarin enweghị mmetụta na ihe ndị na-emepụta ihe na-emepụta ihe na-emepụta ihe na-emepụta ihe na-emepụta ihe na-emepụta ihe na-emepụta ihe na-eme ka ọ dị ngwa ngwa.Dabigatran, tumadi site na mgbochi kpọmkwem nke ọrụ thrombin (prothrombin IIa), na-enwe mmetụta anticoagulant.Rivaroxaban, tumadi site na igbochi ọrụ nke coagulation Factor Xa, si otú a na-ebelata mmepụta nke thrombin (coagulation factor IIa) na-egosipụta anticoagulant mmetụta, adịghị emetụta ọrụ nke thrombin emepụtarala, ya mere enwechaghị mmetụta na physiological hemostasis ọrụ.
2. Ihe ngosi ụlọ ọgwụ nke rivaroxaban vaskụla endothelial endothelial, ọbara na-adịghị ngwa ngwa, hypercoagulability ọbara na ihe ndị ọzọ nwere ike ịkpalite thrombosis.N'ụfọdụ ndị ọrịa orthopedic, ịwa ahụ ngbanwe hip ma ọ bụ ikpere na-aga nke ọma, mana ha na-anwụ na mberede mgbe ha si n'àkwà bilie ụbọchị ole na ole ka a wachara ahụ ahụ.Nke a nwere ike ịbụ n'ihi na onye ọrịa ahụ malitere thrombosis miri emi mgbe a wachara ya ahụ wee nwụọ n'ihi ụbụrụ pulmonary nke thrombus na-ewepụ.Rivaroxaban, ka akwadoro maka iji ya mee ihe na ndị ọrịa toro eto na-arụ ọrụ ngbanwe hip ma ọ bụ ikpere iji gbochie thrombosis venous (VTE);na maka ọgwụgwọ thrombosis miri emi (DVT) na ndị okenye iji belata ihe ize ndụ nke nlọghachite DVT na pulmonary embolism (PE) mgbe nnukwu DVT gasịrị.Atrial fibrillation bụ ọrịa obi arrhythmia a na-ahụkarị nke nwere ihe ruru 10% n'ime ndị mmadụ karịrị afọ 75.Ndị ọrịa nwere fibrillation atrial na-enwe mmasị na ọbara na-adaba na atria ma na-emepụta mkpụkọ, nke nwere ike ịkwasa ma bute ọrịa strok.Rivaroxaban, akwadoro ma kwadoro ya maka ndị okenye na-arịa ọrịa na-abụghị valvular atrial fibrillation iji belata ihe ize ndụ nke ọrịa strok na usoro embolism.Ịdị irè nke rivaroxaban adịghị ala karịa nke warfarin, ọnụ ọgụgụ nke hemorrhage intracranial dị ala karịa nke warfarin, ọ dịghịkwa mkpa na-eleba anya mgbe nile nke ọgwụ mgbochi ọrịa, wdg.
3. Mmetụta anticoagulant nke rivaroxaban bụ nke a na-ahụ anya, nke nwere windo ọgwụgwọ obosara, enweghị nchịkọta mgbe ọtụtụ doses gasịrị, yana mmekọrịta ole na ole na ọgwụ na nri, ya mere nlekota coagulation oge niile adịghị mkpa.N'ọnọdụ pụrụ iche, dị ka a na-enyo enyo na ọ gafechara, ihe omume ọbara ọgbụgba siri ike, ịwa ahụ mberede, ihe omume thromboembolic ma ọ bụ nke a na-enyo enyo na ọ dịghị mma, mkpebi nke oge prothrombin (PT) ma ọ bụ mkpebi nke anti-factor Xa chọrọ.Ndụmọdụ: Rivaroxaban bụ isi metabolized site na CYP3A4, nke bụ mkpụrụ nke protein transporter P-glycoprotein (P-gp).Ya mere, a gaghị eji Rivaroxaban mee ihe na itraconazole, voriconazole na posaconazole.